Evaluation of Rho kinase inhibitor effects on neuroprotection and neuroinflammation in an ex-vivo retinal explant model

Élodie Reboussin,Paul Bastelica,Ilyes Benmessabih,Arnaud Cordovilla,Cécile Delarasse,Annabelle Réaux-Le Goazigo,Françoise Brignole-Baudouin,Céline Olmière,Christophe Baudouin,Juliette Buffault,Stéphane Mélik Parsadaniantz
DOI: https://doi.org/10.1186/s40478-024-01859-z
2024-09-21
Acta Neuropathologica Communications
Abstract:Glaucoma is a leading cause of blindness, affecting retinal ganglion cells (RGCs) and their axons. By 2040, it is likely to affect 110 million people. Neuroinflammation, specifically through the release of proinflammatory cytokines by M1 microglial cells, plays a crucial role in glaucoma progression. Indeed, in post-mortem human studies, pre-clinical models, and ex-vivo models, RGC degeneration has been consistently shown to be linked to inflammation in response to cell death and tissue damage. Recently, Rho kinase inhibitors (ROCKis) have emerged as potential therapies for neuroinflammatory and neurodegenerative diseases. This study aimed to investigate the potential effects of three ROCKis (Y-27632, Y-33075, and H-1152) on retinal ganglion cell (RGC) loss and retinal neuroinflammation using an ex-vivo retinal explant model.
neurosciences
What problem does this paper attempt to address?